Yajieshaba extract improves alcohol‑induced liver injury by regulating hepatic lipid metabolism and gut microbiota

Yajieshaba is a traditional herbal formula used in Dai medicine (an ethnic minority medical tradition from Yunnan, China) with a longstanding reputation for protecting the liver. This mouse study tested whether Yajieshaba could counteract the liver damage caused by chronic alcohol consumption, and tried to understand how it works at a biological level. Male mice were fed an alcohol-containing diet for eight weeks — a well-validated model of alcoholic liver disease — while simultaneously receiving Yajieshaba. The researchers measured liver injury markers in blood, examined liver and intestinal tissue under the microscope, mapped the fat composition of the liver using mass spectrometry, and profiled the gut bacterial community using DNA sequencing. They found that Yajieshaba reduced liver fat accumulation and injury, and that these benefits were associated with a restoration of healthier gut bacteria and normalisation of how the liver handles fats. Importantly, the formula also appeared to protect the gut lining itself, as shown by preserved levels of tight-junction proteins (the molecular 'seals' between intestinal cells) that alcohol normally degrades. The study frames these effects through the 'gut-liver axis' — the idea that disruption of gut bacteria and the intestinal barrier allows harmful signals to reach the liver and drive disease. While promising, the findings come from an animal model and require human validation before any clinical conclusions can be drawn.

• Yajieshaba co-administration significantly attenuated ethanol-induced liver injury and hepatic steatosis (fat accumulation) in mice fed the Lieber-DeCarli ethanol diet for 8 weeks, as assessed by serum biochemical markers and histology (H&E and Oil Red O staining); specific enzyme values are not reported in the abstract.
• Intestinal barrier integrity was preserved in Yajieshaba-treated mice, evidenced by maintained immunofluorescence staining of tight-junction proteins occludin and ZO-1, which were disrupted in untreated alcohol-fed controls.
• Multi-omics integration (16S rRNA gut microbiota profiling combined with LC-MS hepatic lipidomics) indicated that Yajieshaba's hepatoprotective effect operates through concurrent restoration of gut microbial homeostasis and normalisation of hepatic lipid metabolic pathways, implicating the gut microbiome–lipid metabolism axis as the central mechanism.

This was a controlled preclinical experiment using male C57BL/6 mice divided into groups receiving either the standard Lieber-DeCarli control liquid diet or an ethanol-containing Lieber-DeCarli diet for 8 weeks, with or without concurrent Yajieshaba administration; a pair-feeding design was used to control for caloric differences between groups. Outcomes included serum liver injury biomarkers (biochemical kits), liver histopathology (H&E and Oil Red O staining), intestinal barrier assessment (H&E plus immunofluorescence for occludin and ZO-1), hepatic lipid profiling by liquid chromatography-mass spectrometry (LC-MS), and gut microbiota composition by 16S rRNA gene sequencing. Sample sizes per group are not specified in the abstract. The study is published in BMC Complementary Medicine and Therapies (2026) and originates from a Chinese research group.

Because this is an animal study using an 8-week liquid-diet model, it cannot establish efficacy or safety in humans, and the pharmacokinetics and bioavailability of Yajieshaba constituents in humans are unknown. The abstract does not report the specific dose of Yajieshaba used, group sample sizes, or individual statistical effect sizes, making independent appraisal of the magnitude of benefit difficult. The Lieber-DeCarli model approximates early or moderate alcoholic liver disease but may not fully recapitulate the advanced fibrosis or cirrhosis seen clinically. Critical next steps would include identifying the active chemical constituents responsible for the observed effects, replicating findings in a fibrosis/cirrhosis model, and conducting a phase I human pharmacokinetic and safety study.

This study sits within the corpus's growing focus on gut-liver axis mechanisms in liver and mucosal disease. It directly parallels [§152], which investigates a different traditional formula (Sichuan dark tea with a medicine-food-homology blend) using similarly designed mouse alcohol models and gut microbiota profiling, providing a useful comparative reference for herbal ALD interventions. It also parallels [§145], where green tea polyphenol nanoparticles modulate gut microbiota and hepatic metabolic pathways to improve liver health, reinforcing the cross-study pattern that diverse bioactive compounds converge on the microbiota–lipid metabolism axis. The intestinal tight-junction (occludin, ZO-1) data extends the barrier-integrity theme shared with [§148], which demonstrates that dietary intervention with millet starch ameliorates gut leakiness and dyslipidaemia in a high-fat diet model, suggesting that restoration of barrier proteins is a broadly conserved mechanism across metabolic-diet interventions. Finally, the multi-omics design (16S rRNA + lipidomics) parallels the analytical approach used in [§143], which applies multi-omics to characterise probiotic protection in autoimmune hepatitis, underscoring the corpus's methodological convergence on integrated microbiome-metabolome profiling for gut-liver disease research.

• Sichuan dark tea with a medicine-food-homology formula synergistically alleviates alcohol-associated gut microbiota disturbance, liver steatosis and death in mice
  Most directly comparable study: investigates a different traditional/food-homology formula for alcohol-associated liver disease in mice using the same experimental paradigm (gut microbiota + lipid metabolism readouts), enabling head-to-head comparison of herbal ALD strategies.
• Green tea polyphenol-iron oxide chitosan nanoparticles modulate gut microbiota and regulate metabolic pathways
  Both studies show that bioactive compounds restore gut microbiota balance and normalise hepatic lipid metabolism to protect the liver, but the agent here is a synthetic nanoparticle formulation rather than a traditional herbal extract, allowing comparison of mechanism convergence across very different compound classes.
• Dietary Intervention with Brown Top Millet Starch Ameliorates Dyslipidaemia and Gut Leakiness in High Fat Diet Fed Models
  Shares the outcome of restored intestinal barrier integrity (reduced gut leakiness) and dyslipidaemia correction through a dietary intervention in a rodent metabolic-disease model, offering a useful parallel for the tight-junction and lipid findings reported here.
• Multi-omics Analysis Reveals the Protection of a Quadruple Probiotic Mixture in Experimental Autoimmune Hepatitis
  Applies a comparable multi-omics gut-liver axis framework (microbiota profiling combined with metabolic readouts) to a different liver disease aetiology (autoimmune hepatitis vs. alcoholic liver disease), making it a valuable methodological and mechanistic comparator.
• Combined heat and exercise stress disrupt gut microbiota and promote microbial translocation
  Also uses C57BL/6 mice and 16S rRNA sequencing to study gut microbiota disruption and microbial translocation under a physiological stressor, providing a non-alcohol baseline for interpreting how severely alcohol reshapes the microbiome relative to other stressors.